Seres Therapeutics, Inc. Variable Lease, Cost
Seres Therapeutics, Inc. (MCRB) reported Variable Lease, Cost of $1.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-05
- Seres Therapeutics, Inc. variable lease, cost for the quarter ending 2026-06-30 was $1.40M, a 18.88% decline year-over-year.
- Seres Therapeutics, Inc. variable lease, cost for the quarter ending 2026-03-31 was $1.76M, a 41.55% increase year-over-year.
- Seres Therapeutics, Inc. variable lease, cost for the quarter ending 2025-12-31 was $1.76M, a 104.53% increase year-over-year.
- Seres Therapeutics, Inc. variable lease, cost for the quarter ending 2025-09-30 was $1.75M, a 3.11% decline year-over-year.
- Seres Therapeutics, Inc. variable lease, cost for fiscal 2025 was $6.47M, a 1.85% decline from fiscal 2024.
- Seres Therapeutics, Inc. variable lease, cost for fiscal 2024 was $6.59M, a 8.85% decline from fiscal 2023.
- Seres Therapeutics, Inc. variable lease, cost for fiscal 2023 was $7.23M, a 58.98% increase from fiscal 2022.
- Seres Therapeutics, Inc. variable lease, cost for fiscal 2022 was $4.55M, a 37.79% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.40M 10-Q · filed 2026-08-05 | $3.15M 10-Q · filed 2026-08-05 | $4.91M derived: sum of 3 quarters · filed 2026-08-05 | $6.66M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.76M 10-Q · filed 2026-05-05 | $3.52M derived: sum of 2 quarters · filed 2026-05-05 | $5.26M derived: sum of 3 quarters · filed 2026-05-05 | $6.98M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.50M derived: sum of 2 quarters · filed 2026-03-12 | $5.22M derived: sum of 3 quarters · filed 2026-08-05 | $6.47M 10-K · filed 2026-03-12 |
| 2025-09-30 | $1.75M 10-Q · filed 2025-11-05 | $3.47M derived: sum of 2 quarters · filed 2026-08-05 | $4.71M 10-Q · filed 2025-11-05 | $5.57M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.72M 10-Q · filed 2026-08-05 | $2.96M 10-Q · filed 2026-08-05 | $3.82M derived: sum of 3 quarters · filed 2026-08-05 | $5.62M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.24M 10-Q · filed 2026-05-05 | $2.10M derived: sum of 2 quarters · filed 2026-05-05 | $3.90M derived: sum of 3 quarters · filed 2026-05-05 | $5.86M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $860.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.66M derived: sum of 2 quarters · filed 2026-03-12 | $4.62M derived: sum of 3 quarters · filed 2026-03-12 | $6.59M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.80M 10-Q · filed 2025-11-05 | $3.76M derived: sum of 2 quarters · filed 2025-11-05 | $5.73M 10-Q · filed 2025-11-05 | $7.32M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $1.96M 10-Q · filed 2025-08-06 | $3.93M 10-Q · filed 2025-08-06 | $5.51M derived: sum of 3 quarters · filed 2026-03-12 | $7.21M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $1.97M 10-Q · filed 2025-05-07 | $3.55M derived: sum of 2 quarters · filed 2026-03-12 | $5.25M derived: sum of 3 quarters · filed 2026-03-12 | $7.43M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.29M derived: sum of 2 quarters · filed 2026-03-12 | $5.46M derived: sum of 3 quarters · filed 2026-03-12 | $7.23M 10-K · filed 2026-03-12 |
| 2023-09-30 | $1.70M 10-Q · filed 2024-11-13 | $3.88M derived: sum of 2 quarters · filed 2024-11-13 | $5.64M 10-Q · filed 2024-11-13 | $6.75M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $2.18M 10-Q · filed 2024-08-13 | $3.94M 10-Q · filed 2024-08-13 | $5.05M derived: sum of 3 quarters · filed 2025-03-13 | $6.19M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $1.76M 10-Q · filed 2024-05-08 | $2.87M derived: sum of 2 quarters · filed 2025-03-13 | $4.01M derived: sum of 3 quarters · filed 2025-03-13 | $5.28M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $2.25M derived: sum of 2 quarters · filed 2025-03-13 | $3.52M derived: sum of 3 quarters · filed 2025-03-13 | $4.55M 10-K · filed 2025-03-13 |
| 2022-09-30 | $1.14M 10-Q · filed 2023-11-02 | $2.41M derived: sum of 2 quarters · filed 2023-11-02 | $3.44M 10-Q · filed 2023-11-02 | $4.56M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $1.27M 10-Q · filed 2023-08-08 | $2.30M 10-Q · filed 2023-08-08 | $3.42M derived: sum of 3 quarters · filed 2024-03-05 | $4.18M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $1.03M 10-Q · filed 2023-05-09 | $2.15M derived: sum of 2 quarters · filed 2024-03-05 | $2.91M derived: sum of 3 quarters · filed 2024-03-05 | $3.63M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $1.88M derived: sum of 2 quarters · filed 2024-03-05 | $2.60M derived: sum of 3 quarters · filed 2024-03-05 | $3.30M 10-K · filed 2024-03-05 |
| 2021-09-30 | $758.00K 10-Q · filed 2022-11-02 | $1.48M derived: sum of 2 quarters · filed 2022-11-02 | $2.18M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $721.00K 10-Q · filed 2022-08-03 | $1.42M 10-Q · filed 2022-08-03 | ||
| 2021-03-31 | $703.00K 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | $2.89M 10-K · filed 2023-03-07 | |||
| 2019-12-31 | $720.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $1.44M derived: sum of 2 quarters · filed 2022-03-01 | $2.30M derived: sum of 3 quarters · filed 2022-03-01 | $3.02M 10-K · filed 2022-03-01 |
| 2019-09-30 | $716.00K 10-Q · filed 2019-11-05 | $1.58M derived: sum of 2 quarters · filed 2019-11-05 | $2.30M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $860.00K 10-Q · filed 2019-08-06 | $1.59M 10-Q · filed 2019-08-06 | ||
| 2019-03-31 | $726.00K 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |